Your browser doesn't support javascript.
loading
Risk factors for failing to complete gemcitabine-cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients.
Kang, Homin; Suh, Jungyo; You, Dalsan; Jeong, In Gab; Hong, Bumsik; Hong, Jun Hyuk; Ahn, Hanjong; Lim, Bumjin.
Afiliación
  • Kang H; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Suh J; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • You D; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Jeong IG; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Hong B; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Hong JH; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Ahn H; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Lim B; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. lbj1986@hanmail.net.
Investig Clin Urol ; 65(3): 256-262, 2024 May.
Article en En | MEDLINE | ID: mdl-38714516
ABSTRACT

PURPOSE:

We evaluated the risk factors associated with failure to complete gemcitabine-cisplatin (GP) neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC). MATERIALS AND

METHODS:

In total, 231 patients with MIBC treated with NAC before undergoing radical cystectomy between 2013 and 2022 participated in this study. Logistic regression analysis was performed to assess the relationship between the likelihood of incomplete NAC and clinical and demographic variables, including age, sex, hypertension (HTN), diabetes mellitus (DM), prechemotherapy glomerular filtration rate, clinical T stage, clinical N stage, and body mass index (BMI).

RESULTS:

Of 231 patients, 209 (90.5%) and 22 (9.5%) completed and discontinued the NAC course, respectively. The mean age was 66.13±9.15, 65.63±9.07, and 70.86±8.66 years for the total sample, continuation, and discontinuation groups, respectively (p=0.010). No significant inter-group differences in sex, HTN, height, weight, BMI, pre-chemotherapy glomerular filtration rate, clinical T stage, or clinical N stage were observed. According to the results of the multivariable analysis, age (odds ratio [OR] 1.076, 95% confidence interval [CI] 1.013-1.143, p=0.018) and the presence of DM (OR 2.541, 95% CI 1.028-6.281, p=0.043) were significantly associated with NAC discontinuation.

CONCLUSIONS:

Thus, older age and presence of DM are potential risk factors for GP NAC discontinuation in patients with MIBC. Further studies are required to validate our findings and develop strategies to minimize the rate of GP NAC discontinuation in this population.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Protocolos de Quimioterapia Combinada Antineoplásica / Cisplatino / Terapia Neoadyuvante / Desoxicitidina / Gemcitabina / Invasividad Neoplásica Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Investig Clin Urol Año: 2024 Tipo del documento: Article Pais de publicación:
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Protocolos de Quimioterapia Combinada Antineoplásica / Cisplatino / Terapia Neoadyuvante / Desoxicitidina / Gemcitabina / Invasividad Neoplásica Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Investig Clin Urol Año: 2024 Tipo del documento: Article Pais de publicación: